Sight Sciences (NASDAQ:SGHT) Stock: Insider Paul Badawi Sells 29,653 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 29,653 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $268,359.65. Following the transaction, the chief executive officer owned 6,092,819 shares of the company’s stock, valued at $55,140,011.95. The trade was a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Sight Sciences Trading Up 4.6%

Shares of NASDAQ:SGHT traded up $0.39 during mid-day trading on Monday, reaching $8.92. The stock had a trading volume of 564,937 shares, compared to its average volume of 271,241. The firm has a market cap of $491.40 million, a PE ratio of -15.93 and a beta of 2.45. The firm has a 50 day simple moving average of $7.86 and a two-hundred day simple moving average of $5.76. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58. Sight Sciences, Inc. has a twelve month low of $3.19 and a twelve month high of $9.71.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10. The firm had revenue of $23.39 million during the quarter, compared to analysts’ expectations of $21.72 million. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%. On average, research analysts predict that Sight Sciences, Inc. will post -0.52 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on SGHT. Wall Street Zen upgraded Sight Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. UBS Group increased their price target on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. Finally, Citigroup reiterated a “neutral” rating on shares of Sight Sciences in a report on Monday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.88.

Institutional Trading of Sight Sciences

A number of institutional investors have recently modified their holdings of SGHT. BlackRock Inc. bought a new position in shares of Sight Sciences during the second quarter worth about $16,710,000. Dimensional Fund Advisors LP grew its stake in shares of Sight Sciences by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock worth $1,288,000 after acquiring an additional 40,346 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Sight Sciences by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 293,358 shares of the company’s stock worth $1,106,000 after acquiring an additional 17,458 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Sight Sciences in the second quarter valued at approximately $908,000. Finally, Bank of America Corp DE acquired a new stake in shares of Sight Sciences in the second quarter valued at approximately $520,000. 55.51% of the stock is currently owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc is a medical technology company focused on developing and commercializing treatments for ophthalmic diseases. The company designs devices intended to address underlying causes of conditions such as glaucoma and dry eye disease, with an emphasis on less invasive procedures that can be performed in clinical settings.

Its product portfolio includes the OMNI Surgical System, a device used in minimally invasive glaucoma surgery to perform canaloplasty and trabeculotomy procedures.